Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CADL 
Candel Therapeutics Inc (CADL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
- ALL
- 1Y
- 1M
Upturn Advisory Summary
12/02/2025: CADL (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18.62
1 Year Target Price $18.62
| 3 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 167.63% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 245.94M USD | Price to earnings Ratio - | 1Y Target Price 18.62 |
Price to earnings Ratio - | 1Y Target Price 18.62 | ||
Volume (30-day avg) 3 | Beta -0.93 | 52 Weeks Range 4.25 - 14.60 | Updated Date 12/2/2025 |
52 Weeks Range 4.25 - 14.60 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.56 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.1793 | Actual -0.2262 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -43.25% | Return on Equity (TTM) -70.17% |
Valuation
Trailing PE - | Forward PE 43.48 | Enterprise Value 182108905 | Price to Sales(TTM) 436.42 |
Enterprise Value 182108905 | Price to Sales(TTM) 436.42 | ||
Enterprise Value to Revenue 821.98 | Enterprise Value to EBITDA -0.01 | Shares Outstanding 54898303 | Shares Floating 45481597 |
Shares Outstanding 54898303 | Shares Floating 45481597 | ||
Percent Insiders 16.76 | Percent Institutions 41.75 |
Upturn AI SWOT
Candel Therapeutics Inc
Company Overview
History and Background
Candel Therapeutics, Inc. is a late clinical stage biopharmaceutical company focusing on oncolytic viral immunotherapies. Founded in 2003, they aim to develop off-the-shelf therapies to stimulate the immune system and treat solid tumors. Significant milestones include progressing several candidates to clinical trials.
Core Business Areas
- Oncolytic Viral Immunotherapy: Developing and commercializing off-the-shelf oncolytic viral immunotherapies for solid tumors.
Leadership and Structure
Dr. Paul Peter Tak serves as President and CEO. The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- CAN-2409: An off-the-shelf adenovirus-based oncolytic immunotherapy candidate being developed for non-small cell lung cancer, pancreatic cancer, and other solid tumors. No market share yet as it is in clinical trials. Competitors include companies developing similar oncolytic viral therapies and traditional cancer treatments like chemotherapy and targeted therapies.
- CAN-3110: An oncolytic herpes simplex virus (HSV) immunotherapy for the treatment of high-grade glioma (HGG). No market share yet as it is in clinical trials. Competitors include companies developing CAR-T cell therapies, gene therapies, and other novel treatments for brain tumors.
Market Dynamics
Industry Overview
The oncolytic virus immunotherapy market is growing rapidly, driven by advancements in gene therapy and immunotherapy and increasing demand for novel cancer treatments. The market is competitive, with numerous companies developing oncolytic viral therapies.
Positioning
Candel Therapeutics is positioned as a company focused on developing off-the-shelf oncolytic viral immunotherapies for a variety of solid tumors. They are competing with both established pharmaceutical companies and smaller biotech firms.
Total Addressable Market (TAM)
The TAM for oncolytic virus therapies is expected to reach billions of dollars in the coming years. Candel is positioned to capture a share of this market by focusing on unmet needs in solid tumor treatment.
Upturn SWOT Analysis
Strengths
- Proprietary oncolytic virus platform
- Diverse pipeline of clinical-stage product candidates
- Experienced management team
- Focus on unmet needs in solid tumor treatment
Weaknesses
- Limited commercialized products
- Dependence on clinical trial success
- High cash burn rate
- Competition from larger pharmaceutical companies
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition by a larger company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other cancer therapies
- Economic downturn
Competitors and Market Share
Key Competitors
- AMGN
- MRTX
- VRDN
Competitive Landscape
Candel faces competition from established pharmaceutical companies with significant resources and established products, as well as smaller biotech firms developing competing oncolytic viral therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is primarily focused on research and development.
Future Projections: Future growth is dependent on the successful development and commercialization of its product candidates.
Recent Initiatives: Recent initiatives include advancing clinical trials for CAN-2409 and CAN-3110, and exploring potential partnerships.
Summary
Candel Therapeutics is a clinical-stage biopharmaceutical company with promising oncolytic viral immunotherapy candidates. The company's success hinges on positive clinical trial outcomes. Candel needs to carefully manage its cash burn rate and navigate a competitive landscape dominated by larger players.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Candel Therapeutics Inc
Exchange NASDAQ | Headquaters Needham, MA, United States | ||
IPO Launch date 2021-07-27 | President, CEO & Director Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 38 | Website https://www.candeltx.com |
Full time employees 38 | Website https://www.candeltx.com | ||
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.